Talazoparib Tosylate Patent Expiration
Talazoparib Tosylate is used for treating advanced breast cancer and metastatic prostate cancer with specific gene mutations. It was first introduced by Pfizer Inc
Talazoparib Tosylate Patents
Given below is the list of patents protecting Talazoparib Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Talzenna | US10189837 | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt | Oct 20, 2031 | Pfizer |
| Talzenna | US8735392 | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt | Oct 20, 2031 | Pfizer |
| Talzenna | US10780088 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | Jul 27, 2029 | Pfizer |
| Talzenna | US8012976 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | Jul 27, 2029 | Pfizer |
| Talzenna | US8420650 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | Jul 27, 2029 | Pfizer |
| Talzenna | US9820985 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | Jul 27, 2029 | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Talazoparib Tosylate's patents.
Latest Legal Activities on Talazoparib Tosylate's Patents
Given below is the list recent legal activities going on the following patents of Talazoparib Tosylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) | 31 Jul, 2025 | US8012976 |
| Email Notification | 31 Jul, 2025 | US8012976 |
| Notice of Final Determination -Eligible | 09 Jul, 2025 | US8012976 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US8012976 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8012976 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2025 | US9820985 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Sep, 2024 | US8420650 |
| transaction for FDA Determination of Regulatory Review Period | 11 Sep, 2024 | US8012976 |
| transaction for FDA Determination of Regulatory Review Period | 08 Aug, 2024 | US8012976 |
| Application ready for PDX access by participating foreign offices | 28 May, 2024 | US8012976 |
Talazoparib Tosylate's Family Patents
